杞蓟制剂对非酒精性脂肪性肝炎大鼠肝组织过氧化物酶体增殖物激活受体α mRNA的影响

doi:10.3969/j.issn.1672-5069.2010.05.007

摘要/Abstract

摘要： 目的观察杞蓟制剂对非酒精性脂肪性肝炎（NASH）大鼠肝组织过氧化物酶体增殖物激活受体α（PPARα）mRNA表达的影响。方法采用高脂饮食制备大鼠NASH模型，分别给予杞蓟制剂或复方蛋氨酸胆碱处理。采用原位杂交技术检测肝组织PPARα mRNA水平。结果通过图像分析显示，与正常组（0.0457±0.0049）比，模型组大鼠肝组织PPARα mRNA表达的平均吸光度（0.0264±0.0036）明显减弱（P<0.01）；与模型组比，杞蓟制剂和复方蛋氨酸胆碱防治大鼠肝组织PPARα mRNA表达的平均吸光度分别为0.0385±0.0042和0.0353±0.0037，水平明显增高（P<0.05），而杞蓟制剂与复方蛋氨酸胆碱处理组间无显著性差异（P>0.05）。结论杞蓟制剂通过激活PPARα mRNA表达来调节脂质代谢，发挥防治NASH发生的作用。

关键词: 非酒精性脂肪性肝炎, 过氧化物酶体增殖物激活受体α, 杞蓟制剂, 大鼠

Abstract: Objective To study the effect of Qi Ji preparation on mRNA expression of peroxisome proliferator activated receptor α（PPARα）in hepatic tissue of rats with nonalcoholic steatohepatitis. Methods The NASH model of rat was made by high fat diet. The rats were randomly divided into normal control，model，Qi Ji preparation and methionine/choline compound treated group. The mRNA expression of PPARα in hepatic tissues of rats was detected by useing in situ hybridization. Results By means of image analysis，the PPARα mRNA expression in model animals decreased（P<0.05）as compared with that in normal control group；QiJi preparation and methionine/choline compound increased the PPARα mRNA levels obviously. Conclution QiJi preparation could increase the PPARα mRNA expression in hepatic tissues.

Key words: Nonalcoholic steatohepatitis, Peroxisome proliferator activated receptor α, QiJi preparation, Rat

严红梅，刘林，孟培燕，张爱忠，张赤志. 杞蓟制剂对非酒精性脂肪性肝炎大鼠肝组织过氧化物酶体增殖物激活受体α mRNA的影响[J]. 实用肝脏病杂志, 2010, 13(5): 339-341.

YAN Hongmei，LIU Lin，MENG Peiyan，et al.. The effect of QiJi preparation on mRNA expression of peroxisome proliferator activated receptor α in hepatic tissues of rats with nonalcoholic steatohepatitis[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2010, 13(5): 339-341.

参考文献

[1] FARREL GC. Non-alcoholic steatohepatitis:What is it，and why is it important in the Asia-pacific region[J]. J Gastroenterol Hepatol，2003，18:124-138.
[2] BRUNTEM. Non-alcoholic steatohepatitis: definition and pathology[J]. Seminar Liver Dis，2001，21（1）:B3-16.
[3] MORENO SANCHEZ D. Pathogenesis of primary nonalcoholic fatty liver disease[J]. Med Clin/（barc），2005，124（17）:668-677.
[4] 张爱忠，张赤志，许汉林，等. 杞蓟制剂防治非酒精性脂肪性肝炎的实验研究[J]. 中医药通报，2005，4（6）:57-60.
[5] 张爱忠，张赤志，许汉林，等. 杞蓟制剂对非酒精性脂肪性肝炎大鼠肝组织TNFa蛋白表达的影响[J]. 中西医结合肝病杂志，2006，16（3）:153-154.
[6] 张爱忠，张赤志，许汉林，等. 杞蓟制剂对非酒精性脂肪性肝炎大鼠肝组织核转录因子-kB/I kB的影响[J]. 实用肝脏病杂志，2007，10（4）:226-228.
[7] 钟岚，范建高. 非酒精性脂肪肝动物模型[J]. 国外医学.消化系疾病分册，1999，19（3）:175-178.
[8] ISSEMANN I，GREEN S. Activation of a number of the steroid receptor superfamily by peroxisome proliferators[J]. Nature，1990，347:645-650.
[9] GREGOIRE F，SMAS C，SUL H，et a1. Understanding adipocyte differentiation[J]. Physiol Rev，1998，78:783-809.
[10] GUAN Y，BREYER MD. Targeting peroxisome proliferator-activated receptors（PPARs）in kidney and urologic disease[J]. Minerva Urol Nefro1，2002，54:65-79.
[11] DESVERGNE B，WAHLI W. Peroxisome proliferator-activated receptors: nuclear control of metabolism[J]. Endocr Rev，1999，20:649-688.
[12] SCHOONJANS K，LEVENTON GS，EVANS HL，et al. Role of the peroxisome proliferator-activated receptor（PPAR）in mediating the effects of fihrates and fatty acids on gene expression[J]. J Lipid Res，1996，37（5）:907-923.
[13] MANO H，KIMURA C，FUJISAWA Y，et al. Cloning and function of rabbit peroxisome proliferator-activated receptor delta/beta in mature osteoclasts[J]. J Biol Chem，2000，275（11）:8126-8132.
[14] VU-DAC N，SCHOONJANS K，KOSYKH V，et al. Fibrates increase human apolipoprotein A-II expression through activation of the peroxisome proliferator-activated receptor[J]. J Clin Invest，1995，96（2）:741-750.
[15] BERTHOU L，DUVERGER N，EMMANUEL F，et al. Opposite regulation of human versus mouse apolipoprotein A-I by fibrates in human apolipoprotein A-I transgenic mice[J]. J Clin Invest，1996，97（11）:2408-2416.
[16] TENENBAUM A，MOTRO M，SCHWAMMENTHAI E，et a1.Macrovascular complications of metabolic syndrome：an early intervention is imperative[J]. Int J Cardiol，2004，97:167-172.
[17] NEUSCHWANDER-TETRI BA，CALDWELL SH. Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference[J]. Hepatology，2003，37（5）:1202-1219.
[18] NEVE BP，FRUCHART JC，STAELS B. Role of the peroxisome proliferator-activated receptors（PPAR）in atherosclerosis[J]. Biochem Pharmacol，2000，60（8）:1245-1250.
[19] KON K，IKEJIMA K，HIROSE M，et al. Pioglitazone prevents early-phase hepatic fibrogenesis caused by carbon tetrachloride[J]. Biochem Biophys Res Commun，2002，291（1）:55-61.
[20] FURUHASHI M，URA N，MURAKAMI H，et al. Fenofibrate improves insulin sensitivity connection with inrra muscular lipid content muscle fatty acid-binding protein，andβ-oxidation in skeletal muscle[J]. J Endocrinol，2002，174（2）:321-329.
[21] YAMAUCHI T，KAMOM J，WAKI H，et al. Globular adiponectin protected ob/ob mice from diabetes and ApoE-deficient mice from atherosclerosis[J]. Biol Chem，2003，278:2461-2468.
[22] FERRE P. The biology of peroxisome proliferator-activated receptors: relationship with lipid metabolism and insulin sensitivity[J]. Diabetes，2004，53 Suppl 1:S43-50.
[23] KOH EH，KIM MS，PARK JY，et a1. Peroxisome proliferators-activated. receptor（PPAR）-alpha activation prevents diabetes in OLETF rats：comparison with PPAR-gamma activation[J]. Diabetes，2003，52:233l-2337.